Enhancing the therapeutic efficacy of Xanthohumol: A Review of Nanoparticle-Based Anti-Neoplastic Drug Delivery Systems

Introduction

Xanthohumol (XN), a prenylated chalcone derived from hops (Humulus lupulus), has gained attention over the years for its pharmacological properties, such as its antineoplastic, anti-inflammatory, and antioxidative effects. Extensive research has demonstrated XN’s ability to modulate key oncogenic pathways, inhibit metastasis, and induce apoptosis in a variety of cancer types, including breast, prostate, pancreatic, and hematologic malignancies. However, the effective therapeutic application of XN is limited due to poor bioavailability, rapid metabolism, and low systemic absorption. Recent advances in drug delivery, particularly nanoparticle (NP) based approaches, offer potential solutions to these challenges. This review examines the mechanisms of XN's anticancer activity, explores its potential clinical applications, and discusses strategies to enhance its bioavailability using multiple nanotechnology-based formulations.

Methods

A comprehensive literature review was conducted to analyze in vitro and in vivo studies on XN's anticancer effects. Data were collected from recent studies investigating XN's impact on malignant cell proliferation, apoptosis induction, angiogenesis inhibition, and metastasis suppression. Additionally, recent advancements in drug delivery technologies, including polymeric NPs, liposomal NPs, and ligand-conjugated NPs, were reviewed to assess their potential for enhancing XN’s bioavailability and therapeutic efficacy.

Results

XN exhibits broad-spectrum anticancer activity across multiple tumor types through its ability to modulate signaling pathways such as NF-κB, PI3K/Akt, and MAPK. In vitro studies show that XN induces apoptosis via caspase activation and cell cycle arrest, while in vivo models report significant tumor suppression with minimal systemic toxicity. Oral administration studies indicate that XN has low gastrointestinal absorption, a short plasma half-life, and is rapidly metabolized, rendering it ineffective in its unadulterated form. To address these limitations, NP-based delivery systems have been shown to significantly improve XN's stability, cellular uptake, and tumor-targeting capabilities. Among these, ligand-functionalized NPs and polymeric drug carriers have shown the most promise, enabling enhanced tumor permeability and retention as well as controlled drug release.

Discussion and Conclusion

XN’s potent anticancer effects, minimal impact on non-cancerous cells, and overall favorable safety profile make it an acceptable candidate for clinical use. However, improving XNs pharmacokinetics is crucial for its therapeutic viability. The integration of XN with nanotechnology-based drug delivery systems, in particular targeted NPs, holds the potential to overcome bioavailability challenges. Future research should focus on optimizing these formulations, exploring combination therapies with existing chemotherapeutic agents, and conducting clinical trials to validate their effectiveness across multiple cancer types. As advances in precision medicine and nanotechnology continue, XN has repeatedly shown promise as a potent alternative or adjunct to conventional therapies such as Bortezomib or Cisplatin.